September 2024—Thermo Fisher Scientific is partnering with the National Cancer Institute on the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella trial to help accelerate research into new treatments for acute myeloid leukemia and myelodysplastic syndrome. The study involves testing patients’ bone marrow and blood for certain genetic biomarkers using Thermo Fisher’s next-generation sequencing technology so clinical sites can more quickly match patients with an appropriate clinical trial that tests a treatment designed to target specific mutations present in the samples.
The study aims to deliver results within a few days across testing modalities to help quickly enroll patients into specific substudies based on their biomarker profile at time of diagnosis. Thermo Fisher’s Ion Torrent Genexus system automates the specimen-to-report workflow and is designed to deliver results in one day.
Thermo Fisher Scientific, 781-622-1000